Welcome to our dedicated page for ABPRO HLDGS SEC filings (Ticker: ABP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Abpro Holdings, Inc. (Nasdaq: ABP) SEC filings page on Stock Titan provides access to the company’s official U.S. regulatory documents, including current reports, registration statements, and other disclosures filed with the Securities and Exchange Commission. These filings offer detailed insight into Abpro’s biotechnology business, its antibody therapeutic programs, capital structure, and Nasdaq listing status.
Abpro’s filings include multiple Form 8-K current reports describing material events such as reverse stock split approval and implementation, Nasdaq listing notices and hearing outcomes, submission and clearance of an Investigational New Drug (IND) application for ABP-102 / CT-P72, and scientific data presentations in collaboration with Celltrion. These documents help investors understand how Abpro is addressing listing requirements, advancing its lead HER2 × CD3 T-cell engager into Phase 1 trials, and communicating key operational changes.
The company has also filed registration statements, including a Form S-1 related to a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. That prospectus explains how Abpro may direct YA to purchase shares of common stock, outlines potential resale of those shares, and discusses associated risks. Together with other filings, it sheds light on Abpro’s financing arrangements and its status as an emerging growth and smaller reporting company.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight the core points of lengthy documents such as registration statements and complex 8-Ks. Users can quickly see what each filing covers—whether it relates to clinical development of ABP-102 / CT-P72, changes in capital structure, or Nasdaq compliance—while retaining the ability to review the full text from EDGAR. The filings page also surfaces information about Abpro’s listed securities, including common stock (ABP) and warrants (ABPWW), and captures ongoing updates as new reports are filed.
Abpro Holdings (ABP) filed an 8-K/A amending Item 7.01 to replace the press release furnished as Exhibit 99.1 dated November 4, 2025. The company states no other changes were made to the original report.
The information under Item 7.01 and Exhibit 99.1 is furnished, not deemed filed for purposes of Section 18 of the Exchange Act, and is not incorporated by reference unless expressly stated.
Abpro Holdings (ABP) reported that it and Celltrion will present new preclinical data for CT-P72/ABP-102, a tetravalent bispecific antibody targeting HER2 and CD3, at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. The meeting runs November 6–10, 2025 at the Gaylord National Resort and Convention Center in National Harbor, Maryland.
The disclosure was furnished under Item 7.01 (Regulation FD), and a related press release was provided as Exhibit 99.1. This update focuses on scientific progress and does not include financial results or transaction details.
Abpro Holdings, Inc. announced a one-for-thirty reverse stock split that became effective at 5:01 p.m. on October 31, 2025. The company’s common stock will begin trading on a split-adjusted basis on the Nasdaq Global Market on November 3, 2025.
The disclosure was made under Regulation FD via an 8-K, with a press release furnished as Exhibit 99.1.
Abpro Holdings (ABP) announced a one-for-thirty reverse stock split of its common stock, effective at 5:01 p.m. on October 31, 2025. Every 30 shares will be combined into one share, with no change to par value. No fractional shares will be issued; holdings will be rounded up to the next whole share.
Following the split, common shares outstanding will be proportionally reduced from 81,150,000 to approximately 2,705,000. Outstanding stock options and warrants, and their exercise prices, will be adjusted to reflect the new ratio. The company’s transfer agent, Continental Stock Transfer & Trust Company, will handle recordholder communications, while broker-held positions will adjust automatically.
The common stock will begin trading on a split-adjusted basis on November 3, 2025, under the ticker ABP. The new CUSIP for the common stock will be 000847202.
Abpro Holdings (ABP) reported a Nasdaq compliance update. On October 14, 2025, the company received notice that it had not regained compliance with two Nasdaq Global Market standards: the Market Value of Publicly Held Shares requirement of $15,000,000 and the Market Value of Listed Securities requirement of $50,000,000, following a 180-day cure period that ended October 7, 2025.
A hearing before an independent Nasdaq Hearings Panel is scheduled for October 30, 2025, where Abpro plans to present its approach to address the Minimum Bid Price Requirement, MVPHS, and MVLS. Delisting action is stayed pending the Panel’s decision, so ABP common stock and warrants remain listed for now. The company cautioned there is no assurance the Panel will grant continued listing or that compliance can be demonstrated within any extension.
Abpro Holdings reported results of its 2025 annual meeting of stockholders. A 1-for-30 reverse stock split was approved. Ian McDonald was elected as a Class I director until the 2028 annual meeting, and Wolf & Company, P.C. was ratified as independent auditor for the fiscal year ending December 31, 2025.
Voting details: Ian McDonald received 30,544,989 votes for, with 8,122,953 withheld and 10,863,999 broker non-votes. Auditor ratification received 48,873,247 votes for, 380,320 against, and 278,374 abstentions. The reverse stock split at a ratio of 1-for-30 was approved with 26,657,935 votes for.
On the record date, there were 80,166,667 shares outstanding. A quorum was established with 49,531,941 votes represented, approximately 61.8% of eligible votes.
Abpro Holdings, Inc. reports that it has failed to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share by the September 29, 2025 deadline. On September 30, 2025, Nasdaq notified the company that its common stock is subject to delisting.
Unless Abpro appeals by October 7, 2025, its common stock would be scheduled for delisting at the opening of business on October 9, 2025. The company plans to request a hearing before a Nasdaq appeal panel, which will temporarily keep its securities trading while the panel reviews its plans to regain compliance.
Abpro cautions that there is no assurance the panel will grant continued listing or that it will meet all Nasdaq requirements within any extension period that might be provided.
Abpro Holdings, Inc. disclosed that its Chief Medical Officer, Dr. Robert J. Markelewicz, Jr., M.D., M.M.Sc., has been furloughed and will be leaving the company. Effective September 30, 2025, the company placed him on furlough through November 30, 2025, during which he will not perform any duties or responsibilities associated with his role. The filing states that his employment will be terminated effective November 30, 2025, signaling a planned transition away from this key executive position.